Cohort of HIV Associated Lymphomas

Summary

The incidence of lymphomas is increased among HIV infected patients. In 70 % of cases, those are Non Hodgkin's lymphomas (NHL) and Hodgkin lymphomas (HL) in 30% of cases. In France, their incidence is estimated to 100 cases per year (data from the "Base de données Hospitalière Française sur l'Infection à VIH" (FHDH)). The main mechanisms involved in lymphomagenesis are immune dysfunction, involvement of oncogenic viruses (Epstein-Barr (EBV) and HHV8) and molecular oncogenic events. A better understanding of these different pathways, give the possibility to design specific treatments. The treatment of these lymphomas is not standardized. A prospective study of patients with HIV associated lymphoid malignancies is an innovating tool to answer epidemiological, physiopathological and therapeutic questions. We propose a prospective multicentric study of these patients.

The main objectives of this prospective study are to:

* evaluate the incidence, characterise clinically and histologically NHL and HL cases associated to HIV
* perform an observational study of the treatment and outcome of these patients out of the context of clinical trials,
* study the differentiation and activation of B-cell populations,
* better understand the role of specific T cell responses in the control of EBV infection,
* allow other biological studies from the ANRS group " Lymphome et VIH ".

The recruitment of 40 cases per year is expected. The length of inclusions is 7 years. The follow-up will be of 2 years. Clinical, pathological and biological data at diagnosis and during follow-up will be collected. This will allow characterizing the lymphoma, the HIV infection, the antitumoral treatments and the outcome of lymphoma. Biological samples will be centralized to collect cell, DNA, RNA, plasma, serum and tumour collections (Y.Taoufik, S Prevot\* ). To better understand the EBV infection and lymphomagenesis in HIV infection, we propose to follow the viral load and the molecular characteristics of EBV in PBMC, plasma and tumour (P.Morand\* , V.Boyer\* ), to investigate the EBV-T cell responses (G.Carcelain) and the presence and reactivation of EBV in peripheral B cells (C.Amiel\* , JC Nicolas) and in tumoral samples (M.Raphael\* , I.Joab\* ). The other mechanisms of lymphomagenesis in HIV infection will be studied by the analysis of the sub-populations of B-cells in terms of activation and differentiation (Y.Taoufik) and by the characterization of MSI tumours (A.Duval).

Conditions

• HIV Infection

Sponsors & Collaborators

• Dr Yassine Taoufik Dr Houria Chavez Hôpital Bicêtre CIB Paris Sud France

  collaborator UNKNOWN

• Dr Guislaine Garcelain Hôpital Pitié Slapétrière Paris France

  collaborator UNKNOWN

• University Hospital, Grenoble

  collaborator OTHER

• Dr Irène Joab Hôpital Paul Brousse Villejuif France

  collaborator UNKNOWN

• Dr Alex Duval Fondation Jean Dausset CEPH

  collaborator UNKNOWN

• Hopital Antoine Beclere

  collaborator OTHER

• ANRS, Emerging Infectious Diseases

  lead OTHER_GOV

Principal Investigators

• Caroline BESSON · Service Hématologie Immunologie Biologie, Hopital Bicetre

• Gilles Pialoux, PH · Hôpital Tenon Paris

• Marie Caroline Meyonas, PH · Hôpital St Antoine Paris

• Christine Katlama, PH · Hôpital Pitiè Salpétrière

• Jean Gabarre, MD · Hôpital Pitiè Salpétrière Paris

• Dominique Salmon, PH · Hôpital Cochin PARIS

• François Dreyfus, PH · Hôpital Cochin Paris

• Jean Paul Viard, PH · Hotel Dieu PARIS

• Alain Devidas, PH · Corbeil Essone 91

• Emma Goldschmidt, MD · Villejuif 94

• Cecile Goujard, MD · Hôpital Bicêtre 94

• Laurent Blum, MD · Pointoise 95

• François Boué, PH · Clamart 92

• Eric Rosenthal, MD · Nice 06

• Christine Burty, MD · Vandoeuvre les Nancy 54

• Jean Marie Lang, PH · Strasbourg 67

• Renaud Verdon, PH · Caen 14

• Yazdan Yazdanpanah, PH · Tourcoing 59

• Christine Drobacheff, MD · Besancon 25

• Bruno Marchou, PH · Toulouse 31

• Corinne Couteau, MD · Toulouse 31

• Philippe Morlat, PH · Bordeaux 33

• Christian Trepo, PH · Lyon 69

• Hervé Ghesquières, PH · Lyon 69

• Régis Costellos, PH · Marseille

• Bertrand Coiffier, Ph · Pierre Bénite

• Claude Beuscart, MD · St Brieuc 22

• Philippe Perre, MD · La Roche Sur Yon 85

• Patrice Poubeau, MD · St Pierre 97

• François Raffi, PH · Nantes 44

• Frédéric Lucht, PH · St Etienne 42

• Nicolas Mounier, PH · Nice 06

• Cédric Arvieux, PH · Rennes 35

• Serge Herson, PH · Pitié Salpétrière Paris

• Jean François Bergmann, PH · Lariboisière Paris

• André Cabié, PH · Fort de France 97( Martinique)

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-06-30

Primary Completion

2015-06-30

Completion

2017-06-30

Countries

• France

Study Locations